Data from New Analyses of Studies with Veltassa® Presented

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Data from New Analyses of Studies with Veltassa® Presented at 53rd European Renal Association Congress

REDWOOD CITY, Calif., May 22, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ: RLYP ), a biopharmaceutical company, today announced that data from new analyses of studies with Veltassa ® (patiromer) for oral suspension were presented at the 53 rd Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) in Vienna.  

“Patients with heart failure and chronic kidney disease often have restricted fluid and sodium intake, as these may cause congestive symptoms. We presented new data suggesting Veltassa may bind and remove sodium as well as potassium in the gastrointestinal tract, which may be relevant for these patients,” said Lance Berman, M.D., chief medical officer of Relypsa. “A separate analysis showed Veltassa controlled potassium levels for up to a year in hyperkalemic patients who were taking multiple blood pressure medicines. This is important because the use of certain types of blood pressure medicine is often limited due to the side effect of hyperkalemia.”

Effect of the Potassium Binding Polymer Patiromer on Urine Sodium Excretion in Healthy Adults (#SO008) Presented by David A. Bushinsky, M.D., John J. Kuiper Distinguished Professor of Medicine and of Pharmacology and Physiology at the University of Rochester School of Medicine, and chief of the Nephrology Division at the University of Rochester Medical Center

This analysis of the Phase 1 RLY5016-101 study examined the change in urine excretion of sodium in 32 healthy volunteers treated with Veltassa at doses up to 50.4 grams daily for eight days.

Results showed that:

  • Daily administration of Veltassa resulted in a dose-related decrease in mean urine sodium compared with placebo (p=0.009 across Veltassa doses).
  • The most common adverse events were gastrointestinal events that were mild or moderate in severity. No serious adverse events were reported, and no study participants discontinued treatment because of an adverse event.

Effect of Patiromer for Up to 52 Weeks in Patients with Diabetic Kidney Disease Receiving Combined RAAS Inhibitor Therapy (#SO010) Presented by Alain Romero, Pharm.D., Ph.D., Vice President, Relypsa, Redwood City, California

The AMETHYST-DN study 1  evaluated Veltassa over 52 weeks in hyperkalemic patients with chronic kidney disease (CKD) and type 2 diabetes who were taking renin angiotensin aldosterone system (RAAS) inhibitors, such as angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and mineralocorticoid antagonists. This post-hoc analysis assessed the effect of Veltassa on blood potassium levels in a sub-group of 56 hyperkalemic patients who were receiving at least two RAAS inhibitors to treat their hypertension. Of these, 31 were taking two medicines (an ACE inhibitor and an ARB) and 25 were taking a combination of an ACE inhibitor and/or an ARB as well as a mineralocorticoid antagonist.

Results showed that:

  • Mean blood potassium decreased significantly from baseline to day 3, the first post-baseline visit, in those with mild (p < 0.005) or moderate (p<0.0001) hyperkalemia.
  • Clinically significant decreases in mean blood potassium with Veltassa were sustained throughout 52 weeks.
  • At week 52, the mean change from baseline in systolic blood pressure was -11±3 mmHg and the mean change in diastolic blood pressure was -6±2 mmHg.
  • Veltassa was generally well tolerated in this subgroup of patients. Over 52 weeks, 23 percent of patients reported one or more adverse events related to Veltassa. The two most common related events were constipation (8.9 percent, none severe) and diarrhea (5.4%, none severe). The rate of discontinuations due to adverse events was 8.9 percent.

About Hyperkalemia Approximately 3 million people in the United States with stage 3 or 4 CKD and/or heart failure have hyperkalemia, or elevated blood potassium levels. Hyperkalemia can cause abnormal heart rhythms and even sudden death. There are often no warning signs, meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events. Some medicines that are frequently prescribed to people with CKD and heart failure to help delay progression of their underlying disease can cause hyperkalemia as a side effect. These include RAAS inhibitors, such as ARBs, AAs (aldosterone antagonists) and ACE inhibitors.

About Veltassa Veltassa was approved by the U.S. Food and Drug Administration for the treatment of hyperkalemia in the United States on October 21, 2015, becoming the first medicine in more than 50 years for people with elevated serum potassium.

Veltassa is a potassium binder approved for the treatment of hyperkalemia. Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Made in powder form consisting of smooth, spherical beads, Veltassa is mixed with water (90 milliliters or 3 ounces) and taken once-a-day with food. Veltassa is not absorbed and acts within the gastrointestinal tract. It binds to potassium in exchange for calcium, primarily in the colon. The potassium is then excreted from the body through the normal excretion process.

IMPORTANT SAFETY INFORMATION

The Prescribing Information for Veltassa includes a Boxed Warning that Veltassa binds to many other orally administered medications, which could decrease their absorption and reduce their effectiveness . Other oral medications should be administered at least 6 hours before or 6 hours after Veltassa. Doctors should choose Veltassa or the other oral medication if adequate dosing separation is not possible.

Contraindications Veltassa is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa or any of its components.

Worsening of Gastrointestinal Motility   Use of Veltassa should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because Veltassa may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia Veltassa binds to magnesium in the colon, which can lead to hypomagnesemia.  In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3 percent of patients treated with Veltassa. Approximately 9 percent of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Doctors should monitor serum magnesium and consider magnesium supplementation in patients who develop low serum magnesium levels.

A dverse Reactions The most common adverse reactions (incidence ≥2 percent) were constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence.  Mild to moderate hypersensitivity reactions were reported in 0.3 percent of patients treated with Veltassa and included edema of the lips.

For additional Important Safety Information and Veltassa’s full Prescribing Information, please visit www.relypsa.com/veltassa/prescribing-information .

About Relypsa, Inc. Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, Veltassa (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com .

Forward-Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Relypsa, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the results suggested by the data from new analyses of studies with Veltassa and the potential relevance to patients of such data and the potential importance to patients of data from a separate analysis of Veltassa. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development and commercialization process, including regulatory requirements, Relypsa's substantial dependence on Veltassa, Relypsa's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Veltassa. Relypsa undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Relypsa in general, see Relypsa's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2015 and its Quarterly Report on Form 10-Q for the quarterly period ended March 30, 2016.

_____________________________ 1  Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease. The AMETHYST-DN Randomized Clinical Trial. JAMA , 2015;314(2):151-161.

Contact: Charlotte Arnold Vice President, Corporate Communications and Investor Relations 650.421.9452 IR@relypsa.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 67

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 79

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading

Top 5 Most Recently Viewed Articles

Gate Ventures Backs Japanese Web3 Gaming Innovator double jump.tokyo

Updated Category News Views 276

Gate Ventures Invests in double jump.tokyo Gate Ventures is making a significant impact in the blockchain and gaming sectors with its latest investment in double jump.tokyo Inc., a prominent player in Web3 gaming based in Japan. This strategic investment is part of a larger $10 million funding round led by SBI Investment. This backing represents more than just financial...

Continue Reading
Insights from Gridwise's Gig Mobility Report Highlight Trends

Updated Category News Views 1754

Gridwise Annual Gig Mobility Report Highlights The gig mobility industry is encountering significant challenges as economic conditions evolve. Consumers are feeling the pinch from rising prices, leading to resistance against fare increases. Moreover, driver wages are stagnating, which is causing utilization rates to remain low. As platforms strive for profitability, this...

Continue Reading
Esquire Financial Achieves Historic Stock Surge to $81.89

Updated Category News Views 124

Esquire Financial's Stock Reaches New Heights Esquire Financial Holdings Inc (NASDAQ: ESQ) has celebrated a remarkable achievement as its stock price reached an all-time high of $81.89 recently. This milestone reflects the company's strong financial health and market position, boasting a market capitalization of approximately $638 million. The surge in price signals a...

Continue Reading
Deck Commerce Shines as a Leader in Omnichannel Management

Updated Category News Views 199

Deck Commerce Emerges as a Leading Innovator In the competitive landscape of order management systems, Deck Commerce stands out as a beacon of innovation and excellence. Recently recognized by QKS Group's SPARK Matrix™ for 2025, the company has secured its position as both a leader and emerging innovator in the field. This accolade reflects Deck Commerce's dedication to...

Continue Reading
Porsche Penske Motorsport Celebrates Historic Victory

Updated Category News Views 343

Porsche Penske Motorsport Celebrates Historic Victory Porsche Penske Motorsport has achieved remarkable success at the prestigious 24 Hours of Daytona, clinching its second consecutive win. As the race unfolded, the familiar faces of Felipe Nasr, Nick Tandy, and Laurens Vanthoor led the No. 7 Porsche 963 to victory, marking a milestone as Porsche secured its 20th overall...

Continue Reading